CAR T cell therapy for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma.
- You have already tried at least 4 different types of myeloma treatments, including an immunomodulatory drug, a proteasome inhibitor, an anti-CD38 antibody, and an anti-BCMA therapy.
- Your disease got worse during or after your last treatment.
- You are in generally good physical condition (able to do light work or be up and about).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This study tests a new type of cell therapy called BCMA-GPRC5D CAR-T for people whose multiple myeloma has come back or not responded to standard treatments. The therapy uses your own immune cells, modified in a lab, to find and attack myeloma cells.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.